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Background Mortality in HIV-infected patients has declined substantially with
combination antiretroviral therapy (ART), but it is unclear whether
it has reached that of the general population. We compared
mortality in patients starting ART in nine countries of Europe
and North America with the corresponding general population,
taking into account their response to ART.
Methods Eligible patients were enrolled in prospective cohort studies parti-
cipating in the ART Cohort Collaboration. We calculated the ratio of
observed to expected deaths from all causes [standardized mortality
ratio (SMR)], measuring time from 6 months after starting ART,
according to risk group, clinical stage at the start of ART and
CD4 cell count and viral load at 6 months. Expected numbers
of deaths were obtained from age-, sex- and country-specific mor-
tality rates.
Results Among 29 935 eligible patients, 1134 deaths were recorded in
131 510 person-years of follow-up. The median age was 37 years,
8162 (27%) patients were females, 4400 (15%) were injecting
drug users (IDUs) and 6738 (23%) had AIDS when starting ART.
At 6 months, 23 539 patients (79%) had viral load measurements
4500 copies/ml. The lowest SMR, 1.05 [95% confidence interval
(CI) 0.82–1.35] was found for men who have sex with men
(MSM) who started ART free of AIDS, reached a CD4 cell count
of 5350 cells/mL and suppressed viral replication to 4500 copies/ml
by the sixth month. In contrast, the SMR was 73.7 (95% CI 46.4–
116.9) in IDUs who failed to suppress viral replication and had CD4
cell counts <50 cells/mL at 6 months. The percentage of patients
with SMRs <2 was 46% for MSM, 42% for heterosexually infected
patients and 0% for patients with a history of injection drug use.
Corresponding percentages for SMRs410 were 4, 14 and 47%.
Conclusions In industrialized countries, the mortality experience of HIV-infected
patients who start ART and survive the first 6 months continues to
be higher than in the general population, but for many patients
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excess mortality is moderate and comparable with patients having
other chronic conditions. Much of the excess mortality might be
prevented by earlier diagnosis of HIV followed by timely initiation
of ART.
Keywords HIV-infection, antiretroviral therapy, mortality, general population,
standardized mortality ratio, meta-analysis, industrialized countries
Introduction
The widespread use since 1996 of combination anti-
retroviral therapy (ART) has substantially improved
the prognosis of human immunodeficiency virus
(HIV)-infected patients.1–3 Recent studies have sug-
gested that all-cause mortality in patients successfully
treated with ART might approach that of the general
population, and that in many patients mortality rates
are comparable with other chronic conditions, such as
diabetes.4–8 Such comparisons are important to gain a
better understanding of the treated history of HIV
infection, to monitor and predict the progress of the
HIV/acquired immunodeficiency syndrome (AIDS)
epidemic and to plan health services in the era of
potent ART. These data are also important in the con-
text of life insurance: an increasing number of people
living with HIV/AIDS wish to obtain life insurance,
but many find that such insurance is either not on
offer, of limited scope or expensive.9
Several prognostic factors of mortality have been
identified in HIV-infected patients starting ART.
The ART Cohort Collaboration (ART-CC), an interna-
tional collaboration of cohort studies of HIV-1-
infected patients starting ART, defined prognostic
groups based on the CD4 cell count and viral load
at baseline, age, infection through injection drug use
and a prior diagnosis of AIDS. The probability of
death 3 years after starting ART ranged from 0.8%
in the group at lowest risk to 43% in the highest
risk group.10 A subsequent analysis showed that base-
line CD4 cell count and viral load were no longer
prognostic once the 6-month measurements had
been taken into account.11 The immunological and
virological responses after 6 months of treatment are
therefore important factors predicting disease progres-
sion over subsequent years.
Previous studies comparing the mortality of HIV-1-
infected patients with that of the general population
were based on single cohort studies and therefore had
limited power to compare mortality rates across prog-
nostic groups.4 In the present study we analysed
the ART-CC database to compare mortality rates
observed in 13 cohort studies of HIV-1-infected
patients with those observed in the general popula-
tions of the nine countries concerned. Standardized
mortality ratios (SMRs) were calculated from
6 months after starting ART, thus taking the initial
response to treatment into account.
Methods
ART-CC
The ART-CC is a collaboration of cohort studies and
clinical databases from North America and Europe,
which was established in 2001 to estimate prognosis
in adult HIV-infected patients initiating ART.
Eligibility criteria and methods have been reported
in detail elsewhere.10–13 Briefly, prospective cohort
studies were eligible if they had enrolled at least
100 patients with HIV-1 infection aged 516 years
who had not previously received antiretroviral treat-
ment (treatment-naive) and initiated ART with a
combination of at least three drugs, including nucleo-
side analogue reverse transcriptase inhibitors (NRTIs),
protease inhibitors (PIs) and non-nucleoside analogue
reverse transcriptase inhibitors (NNRTIs), with a
median duration of follow-up of 51 year. The present
analysis was based on the most recent database,
which was assembled in 2007. All patients
with known date of starting ART and who had
a CD4 count and HIV-1 RNA measurement at
6 months were included. We restricted the analysis
to the three most important transmission groups
(via homosexual sexual contacts, via heterosexual
sexual contacts and injection drug use). These three
groups comprise 80% of all patients in the ART-CC
database. Patients who died or were lost to follow-
up within the first 6 months after ART were excluded.
All cohorts follow patients actively, using telephone,
postal reminders or both.
Clinical stage at baseline (the time of starting ART)
was classified as less advanced disease (CDC stage
A/B) or AIDS (CDC stage C).14 Most viral load
determinations were done with the Amplicor
Monitor PCR method (Roche Molecular Systems,
Branchburg, NJ, USA), but the branched DNA
assay (Chiron Diagnostics, Emeryville, CA, USA) and
the NASBA-QT assay (Organon Teknika, Durham, NC,
USA) were also used in some cohorts. We considered
500 copies/ml as the lower limit of detection in order
to overcome heterogeneity in the assays’ detection
levels.
Patient selection and data extraction were per-
formed at the data centres of the participating
cohort studies. Anonymized data on a predefined set
of demographic, laboratory and clinical variables were
then pooled and analysed centrally. Data managers
checked for duplicated records, and ensured that
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patients included in more than one cohort had
only one record in the combined dataset. At all sites
institutional review boards had approved the collec-
tion of data.
Country-specific general population
mortality rates
Sex- and age-specific mortality rates for the general
populations were obtained from the Human Mortality
Database (http://www.mortality.org), a collaborative
project between the Department of Demography at
the University of California, Berkeley, USA, and the
Max Planck Institute for Demographic Research,
Rostock, Germany.
Statistical analysis
We used an ‘intent-to-continue-treatment’ approach
and thus ignored subsequent changes to treatment,
including treatment interruptions and terminations.
We used indirect standardization of rates. Time was
measured from 6 months after starting ART to the
last follow-up visit or death. SMRs were calculated
as the ratio of the number of observed deaths to the
number of expected deaths from all causes, in strata
defined by sex, risk group—injecting drug users
(IDUs), heterosexuals and men who have sex
with men (MSM)—clinical stage at baseline (CDC
A/B, C) and the CD4 cell count and viral load at
6 months. The expected number of deaths for the
corresponding year was calculated by multiplying
the age-specific (in 1-year age bands) and sex-specific
death rates from the corresponding general popula-
tion with the observed follow-up time starting
at 6 months for each participant. 95% confidence
intervals (CIs) for the SMRs were calculated
according to Chiang.15 In a sensitivity analysis we
repeated analyses excluding the largest cohort,
which contributed 42% of the deaths and 46% of
the patients.
Results
The database of the ART-CC includes 49 040 eligible
patients of 10 cohorts from Europe, two cohorts from
Canada and three cohorts from the USA. We excluded
1658 (3.4%) patients from the EuroSIDA study,16
which includes patients from 20 European countries;
and 4980 (10.2%) patients from the Veterans Ageing
Cohort Study (VACS), which has incomplete informa-
tion on transmission group in a large proportion of
patients. We also excluded 4347 (8.9%) patients
whose risk group was unknown or other than hetero-
sexual contacts, sex between men or injection drug
use, and 4925 (10.0%) patients who did not have
both a viral load measurement and CD4 count at
6 months. Finally, we excluded 3195 (6.5%) patients
not followed beyond 6 months, including 347 patients
who died in the first 6 months of ART. The analyses
were thus based on 29 935 (61.0%) patients from the
following 13 cohorts of nine countries: AIDS Therapy
Evaluation Project Netherlands (ATHENA);17 Aquitaine
Cohort, France;18 British Columbia Centre for
Excellence in HIV/AIDS, Canada;2 Collaborations in
HIV Outcomes Research, United States (CHORUS);19
Frankfurt HIV Cohort, Germany;20 French Hospital
Database on HIV (FHDH);21 Italian Cohort of
Antiretroviral-Naive Patients (ICONA);22 Ko¨ln/Bonn
Cohort, Germany;23 Proyecto para la Informatizacio´n
del Seguimento Clı´nico-epidemiolo´gico de la Infeccio´n
por HIV y SIDA (PISCIS), Spain;24 Royal Free Hospital
Cohort, UK;25 South Alberta Clinic, Canada;26 Swiss
HIV Cohort Study (SHCS)1 and University of Alabama
1917 Clinic Cohort, United States.27
The characteristics of the 13 participating cohorts
are shown in Table 1. The number of patients
ranged from 279 to 13 645. The median CD4 cell
count at the start of ART ranged from 159 to 297
cells/mL, and the proportion of patients with a history
of injection drug use ranged from 2 to 44%. A total of
8155 (27%) patients were lost to follow-up by study
end. Compared with those who were alive and in
follow-up at the end of the study period patients
who were lost to follow-up had similar median CD4
counts at 6 months (330 compared with 328 cells/mL),
and the proportion with AIDS at baseline was also
similar (21% compared with 22%). The proportion of
patients who were infected via injection drug use was
slightly higher in those lost to follow-up (18%) com-
pared with those who remained in follow-up (13%).
In patients who died the median CD4 cell count at 6
months was 188 cells/mL, 41% had AIDS and 31% had
a history of injection drug use.
Patient characteristics are shown in Table 2. The
median age was 37 years [interquartile range (IQR)
32–44 years], 8162 (27%) patients were females, 4400
(15%) had a history of injection drug use and 6738
(23%) had AIDS when starting ART. The initial
antiretroviral regimen contained a PI in 18 648
(62%) patients and an NNRTI in 9561 (32%). At
start of the therapy, 27 937 patients (93%) were on
three antiretroviral drugs (counting ritonavir boosted
PI as one drug), the remaining patients were on four
or more drugs. At 6 months, data on drug regimen
prescribed were available in 27 514 patients (92%). In
the remaining patients, data were missing or treat-
ment was stopped before 6 months. A regimen
including a PI was used in 16 315 patients (55%)
and an NNRTI in 8861 patients (30%). Overall,
19 826 (66%) patients remained on their initial com-
bination at 6 months. The median CD4 cell count
increased in the first 6 months, from 216 (IQR 90–
348) to 322 cells/mL (IQR 185–489). At 6 months,
23 539 patients (79%) had viral load measurements
4500 copies/ml. This proportion varied by outcome
status: 59% in those who died, 73% in those lost to
follow-up and 82% in those remaining in follow-up
and alive at the end of the study.
1626 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
 by guest on Septem
ber 1, 2011
ije.oxfordjournals.org
D
ow
nloaded from
 
The median duration of follow-up after 6 months of
ART was 3.75 years. There were 1134 deaths recorded
during a total of 118 975 person-years of follow-up,
for a crude death rate of 0.95 per 100 person-years
(Table 2). The crude SMR over all cohorts was 3.36
(95% CI 3.16–3.56), with some heterogeneity between
cohorts. The cohort-specific, crude SMRs tended to be
higher for cohorts with large proportions of IDUs and
lower median CD4 cell counts at 6 months (data not
shown). SMRs for the three main transmission groups
stratified by clinical stage at baseline and viral load
and CD4 cell count at 6 months are shown in Table 3.
SMRs increased with decreasing CD4 counts at
6 months, were higher if viral load at 6 months was
4500 copies/ml, higher in patients with AIDS at base-
line and higher in IDUs than in homosexual men and
heterosexually infected people. The lowest SMR, 1.05
(95% CI 0.82–1.35), was found for MSM who started
ART free of AIDS and reached a CD4 cell count
of 5350 cells/mL and a viral load of 4500 copies/ml
by the sixth month (Table 3). At the other end of the
spectrum, an SMR of 73.7 (46.4–116.9) was found
in IDUs who started ART with a CD4 cell count
<50 cells/mL and a viral load 4500 copies/ml at
6 months. The group of IDUs with the lowest mortal-
ity had an SMR of 5.59 (4.28–7.29).
Figure 1 shows the cumulative frequency distribu-
tion of SMRs, separately for the three transmission
groups. The figure is based on the number of patients
in the different risk groups shown in Table 3. Among
homosexual men, 5455 (46%) had an estimated
SMR <2, 4937 patients (41%) had an SMR in the
range of 2 to <5, and 448 patients (4%) had an
SMR of 510. The corresponding figures for hetero-
sexually infected patients were 5714 (42%), 5095
(38%) and 1903 (14%). For IDUs the figures were 0
(0%), 0 (0%) and 2055 (47%), respectively. Finally,
sensitivity analyses showed that results were robust
and not driven by a single cohort. In particular,
excluding the largest cohort did not materially alter
results.
Discussion
In this collaborative study involving 13 prospective
studies and more than 29 000 treatment-naive
patients who were followed up for 46 months, the
mortality of HIV-infected patients starting ART
could be compared across many prognostic groups
with that of the corresponding general population.
We found that a substantial proportion of men
infected through sex with men and individuals
infected through heterosexual contacts had SMRs
<2. In other words, in440% of HIV-infected patients
from these transmission groups, mortality was
increased by <100% compared with the general pop-
ulation. In MSM who started ART free of AIDS and
had a CD4 cell count 5350 cells/mL and a viral load of
4500 copies/ml at 6 months after starting ART, this
increase was estimated at 5% (SMR 1.05). Conversely,
mortality was increased470 times (SMR 73.7) in the
small group of patients who were infected through
injection drug use, failed to suppress viral replication
Table 1 Characteristics of the 13 cohorts from nine countries that participated in the analyses
Cohort
No. of
patients,
no. of deaths
and no. lost
to follow-up
Crude
mortality
rate per 100
person-years
of follow-upa
(95% CI)
No. of
women
(%)
No. with
history
of injection
drug use at
baseline
(%)
No. with
AIDS at
baseline
(%)
Median
CD4 cells/mL
at 6
months
(IQR)
No. with
viral load
4500 copies/ml
at 6 months
A 279, 23, 73 1.97 (1.31–2.96) 93 (33) 34 (12) 47 (17) 296 (143–487) 214 (77)
B 648, 22, 80 0.88 (0.58–1.34) 148 (23) 78 (12) 78 (12) 433 (261–589) 535 (83)
C 4380, 154, 732 0.87 (0.74–1.01) 1082 (25) 171 (4) 972 (22) 340 (210–500) 3788 (86)
D 672, 73, 32 2.29 (1.82–2.89) 81 (12) 295 (44) 286 (43) 320 (180–500) 498 (74)
E 434, 17, 95 1.01 (0.63–1.62) 103 (24) 23 (5) 138 (32) 270 (160–410) 348 (80)
F 1055, 34, 370 0.90 (0.65–1.27) 110 (10) 40 (4) 408 (39) 364 (216–552) 773 (73)
G 13 645, 474, 4890 0.87 (0.79–0.96) 4209 (31) 1599 (12) 2981 (22) 312 (177–468) 10 202 (75)
H 1442, 72, 193 1.12 (0.89–1.41) 307 (21) 221 (15) 279 (19) 285 (160–432) 1190 (83)
I 2252, 66, 880 0.73 (0.58–0.93) 630 (28) 797 (35) 372 (17) 385 (216–572) 1656 (74)
K 1705, 41, 208 0.90 (0.66–1.22) 405 (24) 529 (31) 462 (27) 313 (174–491) 1420 (83)
L 655, 5, 99 0.29 (0.12–0.69) 162 (25) 12 (2) 171 (26) 309 (180–485) 560 (85)
M 291, 14, 71 1.08 (0.64–1.82) 55 (19) 57 (20) 85 (29) 288 (183–447) 240 (82)
N 2477, 139, 432 1.31 (1.11–1.54) 777 (31) 544 (22) 459 (19) 321 (183–484) 2115 (85)
All cohorts 29 935, 1134, 8155 0.95 (0.91–1.02) 8162 (27) 4400 (15) 6738 (23) 322 (185–489) 23 539 (79)
aCalculation of time at risk started at 6 months.
CI¼ confidence interval.
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Table 2 Characteristics of 29 935 treatment-naive study patients at baseline and 6 months after the initiation of potent
combination ART
Characteristic
No. of patients
(%)
No. of deaths
(%)
Crude mortality
rate per 100 person-years
of follow-upa
Total 29 935 (100) 1134 (100) 0.95
Age at baseline (years)
16–29 5081 (17) 79 (7) 0.4
30–39 13 376 (45) 457 (40) 0.83
40–49 7646 (26) 343 (30) 1.17
550 3832 (13) 255 (22) 1.75
Sex
Males 21 773 (73) 931 (82) 1.05
Females 8162 (27) 203 (18) 0.68
Risk group
MSM 11 960 (40 388 (34) 0.76
Heterosexuals 13 575 (45) 392 (35) 0.79
IDUs 4400 (15) 354 (31) 1.95
Clinical CDC stage at baseline
A/B 23 197 (77) 668 (59) 0.72
C 6738 (23) 466 (41) 1.77
CD4 count (cells/ml) Baseline measurement
<25 3007 (10) 219 (19) 1.84
25–49 1913 (6) 123 (11) 1.64
50–99 3088 (10) 170 (15) 1.4
100–199 5849 (20) 229 (20) 1.06
200–349 8635 (29) 226 (20) 0.71
5350 7443 (25) 167 (15) 0.49
6-month measurement
<25 442 (1) 101 (9) 7.41
25–49 599 (2) 88 (8) 3.95
50–99 1923 (6) 147 (13) 1.9
100–199 5189 (17) 255 (22) 1.27
200–349 8092 (27) 261 (23) 0.86
5350 13 690 (46) 282 (25) 0.49
Plasma HIV-1 RNA level (copies/ml) Baseline measurement
4500 (undetectable) 433 (1) 15 (1) 0.94
501–9999 3373 (11) 89 (8) 0.67
10 000–99 999 11 931 (40) 350 (31) 0.73
5100 000 14 198 (47) 680 (60) 1.22
6-month measurement
4500 (undetectable) 23 539 (79) 674 (59) 0.73
501–9999 3287 (11) 165 (15) 1.14
10 000–99 999 1984 (7) 142 (13) 1.83
5100 000 1125 (4) 153 (13) 3.71
aCalculation of time at risk started at 6 months.
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and had very low CD4 cell counts at 6 months
(<50 cells/mL). Among IDUs, even the group with
the lowest mortality rates had an SMR45.
How applicable are our estimates to other HIV-
infected patients? The database of the ART-CC
included patients from many countries of Europe
and North America who were treated in different set-
tings. The spectrum of patients was broad: men and
women, from teenagers to elderly people and the
major exposure categories were well represented.
The severity of immunodeficiency at baseline ranged
from very severe to non-existent, and viral replication
from very low to extremely high. Our results should
therefore be applicable to many other patients
from industrialized countries. Recording of deaths in
ART-CC can be assumed to be near complete: in two
cohorts deaths are routinely ascertained from the
national mortality register, and mortality rates in
these two cohorts are similar to the other cohorts.
The large number of patients and deaths analysed
are a strength of our study, even though follow-up
was limited to 4 years. It is possible that mortality
will increase in HIV-infected patients with longer
duration of treatment, although we failed to detect
such a trend in a recent analysis of ART-CC data.13
We stress that our estimates apply only to HIV-
infected patients who survived for at least 6 months
after starting treatment. Mortality in the first months
of ART is high in patients starting ART with low CD4
counts and advanced disease. This early mortality was
not considered in the present analysis, but has been
described in previous reports from the ART-CC collab-
oration.10,13,28 Also, we restricted analyses to patients
infected either through heterosexual sex, sex between
men or injection drug use. The number of patients
infected through other routes, including by blood
transfusions or blood products, was too small to
allow such detailed analyses.
Our analysis did not consider differences between
the HIV-infected population and the corresponding
general population other than gender and age. There
are important differences in the prevalence of risk
factors such as smoking between HIV-infected and
non-infected populations. For example, a collaborative
analysis of HIV cohort studies found that 450% of
HIV-infected patients were smokers.29 In the coun-
tries covered by our study, this proportion will be
lower (20–40%) in men and women of the same age
from the general population.30 Clearly, part of the
increased mortality relative to the general population
may be attributable to other lifestyle factors, and
smoking in particular, rather than to HIV infection.
In an important minority of patients, infection was
associated with the injection of intravenous drugs.
Studies of HIV infected IDUs have repeatedly shown
that they are at increased risk of death from causes
not directly related to HIV infection, including over-
dose, suicide and homicide.31,32 Also, these patients
are known to be at risk of fatal overdose or liver
failure associated with co-infection with hepatitis
C virus (HCV).33,34 We did not consider HCV infection
in our analyses. However, because HCV co-infection is
Table 3 SMRs with 95% CIs by risk group, clinical stage at baseline and CD4 cell count and viral load at 6 months based
on 29 935 patients
Clinical stage at baseline A/B Clinical stage at baseline C
Risk group
6-month
CD4 count
(cells/mL)
6-month viral
load 4500
copies/ml
6-month viral
load4500
copies/ml
6-month viral
load 4500
copies/ml
6-month viral
load4500
copies/ml
MSM 0–49 3.41 (0.85–13.7) 23.4 (13.0–42.2) 9.62 (5.80–16.0) 24.91 (16.55–37.48)
50–99 3.23 (1.68–6.21) 6.59 (2.96–14.7) 4.98 (3.28–7.57) 13.40 (7.93–22.62)
100–199 2.27 (1.57–3.29) 3.52 (2.09–5.95) 3.29 (2.32–4.65) 6.92 (4.24–11.29)
200–349 1.47 (1.07–2.01) 3.50 (2.33–5.27) 2.65 (1.79–3.93) 1.92 (0.80–4.61)
5350 1.05 (0.82–1.35) 2.06 (1.37–3.10) 1.73 (1.01–2.98) 2.48 (0.93–6.61)
Heterosexuals 0–49 8.40 (4.65–15.16) 28.03 (17.2–45.8) 11.2 (6.72–18.5) 25.7 (18.5–35.8)
50–99 4.34 (2.62–7.21) 2.11 (0.68–6.53) 4.24 (2.70–6.64) 12.16 (7.33–20.2)
100–199 2.18 (1.50–3.18) 3.59 (2.26–5.69) 2.91 (1.99–4.24) 5.25 (3.16–8.71)
200–349 1.85 (1.35–2.53) 3.26 (2.03–5.24) 2.25 (1.40–3.62) 4.67 (2.59–8.44)
5350 1.33 (1.00–1.75) 1.88 (1.11–3.17) 2.52 (1.36–4.69) 3.91 (1.63–9.39)
IDUs 0–49 19.1 (9.09–40.0) 73.7 (46.4–116.9) 13.5 (6.43–28.30) 52.8 (35.4–78.7)
50–99 6.31 (3.15–12.6) 20.6 (11.7–36.3) 13.0 (6.47–25.89) 40.5 (23.0–71.3)
100–199 10.3 (7.00–15.1) 14.6 (9.29–22.8) 8.56 (5.07–14.45) 20.5 (12.2–34.7)
200–349 6.44 (4.55–9.10) 15.1 (10.4–22.1) 7.40 (4.20–13.03) 14.6 (7.29–29.2)
5350 5.59 (4.28–7.29) 8.31 (5.42–12.7) 9.39 (5.33–16.54) 24.9 (11.2–55.4)
Standardized mortality ratios (95% confidence intervals).
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mainly found in IDUs, its effect will largely be sub-
sumed in the increased hazard for IDUs in our
analysis.35
There was heterogeneity in the cohort-specific
SMRs, which might be explained by differences both
in HIV-infected patients and general populations. As
noted previously,8 in this type of study the expected
mortality rate for the general population is based
on all causes of deaths and thus includes mortality
in HIV-infected patients. Mortality due to HIV peaked
in the mid-1990s both in Europe36,37 and the USA.38
At that time in some urban regions, for example
Barcelona or Bologna,39 HIV-associated mortality
was responsible for up to 40% of all deaths in
young adults. In 1999 the proportion of deaths attrib-
uted to HIV infection in age group 25–44 years ranged
from 1.2% in Germany to 6.8% in the USA.40 The
proportion of deaths attributable to HIV will be even
lower in older or younger age groups. Therefore,
in the era of potent combination ART, mortality due
to HIV represents only a small proportion of all-cause
mortality in industrialized countries, and substantial
bias can be excluded.
How do these SMRs compare with other population
groups at increased risk of death due to unhealthy
lifestyles or chronic conditions other than HIV infec-
tion? For example, among male British doctors born
in the 1920s, the probability of dying from any cause
in middle age was43 times in smokers than lifelong
non-smokers.41 Similarly, an analysis of the National
Alcohol Survey in the USA showed that regular, heavy
drinkers had mortality rates from all causes that
were 42.2 times than those observed in lifetime
abstainers.42 The mortality of people with a body
mass index (BMI)435 kg/m2 is increased by factor
1.5–2.5, compared with those with a BMI between
20 and 25 kg/m2, and a similar increase in all-cause
mortality is found in physically inactive people
compared with physically active individuals.43 In a
population-based study in Turin, Northern Italy,
women with type 1 diabetes had an SMR for all
causes of 3.4 and men an SMR of 2.44 The corre-
sponding SMRs for type 2 diabetes was 1.4 for both
sexes.44 The SMRs found in these patients and popu-
lations exposed to risk factors are thus quite compa-
rable with those found in some of the patient groups
included in our analysis.
What are the implications of this study? Our results
are, for example, relevant in the context of insurance
protection for HIV-infected individuals. Until recently,
life insurance was not available to HIV-infected indi-
viduals. This study and other studies support the
notion that life insurance plans should be provided
at least to some people living with HIV/AIDS. A
recent analysis from the Agence Nationale de
Recherches sur le Sida et les he´patites virales
(ANRS) APROCO and AQUITAINE cohorts in France
showed that in patients whose CD4 counts increased
to 500 cells/mL, mortality reached that of the general
population after the sixth year on ART.45 The Dutch
Association of Insurers has recommended that HIV-
positive people responding to antiretroviral treatment
who have no other medical complications, and who
are not IDUs, should be eligible for life insurance,
at reasonable costs.46 In the USA, an important bar-
rier for HIV-positive people seeking life insurance
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Figure 1 (a–c) Cumulative frequency distribution of SMRs
for the three main HIV transmission groups
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policies is high cost: premiums have been found to be
two to three times higher for HIV-infected patients,
compared with patients of the same age living with
cancer.46 Of note, a South African insurance company
recently introduced life insurance for people living
with HIV/AIDS.46
Although a substantial proportion of HIV-infected
patients experienced mortality rates that were compa-
rable with that experienced by other patients with a
chronic condition, mortality continues to be much
higher in patients who start treatment late, for exam-
ple, with a history of AIDS-defining illnesses and low
CD4 cell counts. Early diagnosis and treatment are
of great importance to prevent clinical progression
as well as the spread of the infection.47,48 A survey
of new HIV diagnoses in the UK and Ireland
showed that many opportunities for earlier diagnosis
are missed.49 Although our study cannot determine
the CD4 cell count when ART should be started in
order to minimize mortality, much of the excess mor-
tality observed in our study would be preventable
with expanded, voluntary screening in health care
setting; an approach that has been shown to be cost
effective.50 The ART-CC will continue to monitor
the characteristics and mortality of HIV-infected
patients starting ART by updating analyses at regular
intervals.
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